Orforglipron
⚠ Not a peptide — small molecule. A daily oral GLP-1 agonist in Phase 3 for obesity and T2DM, distinct from Rybelsus in being a small molecule rather than an oral peptide formulation. Included in this peptide encyclopedia because the audience frequently searches for it alongside peptide GLP-1 agonists.
An orally bioavailable, non-peptide small molecule that activates the GLP-1 receptor — structurally unrelated to GLP-1 but producing similar pharmacology in Phase 2 trials.
Mechanism of action
Non-peptide allosteric agonist at the GLP-1 receptor. Produces classic GLP-1 pharmacology — enhanced glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, appetite reduction — but with the practical advantages of oral administration, no injection, and no food-timing requirements (unlike Rybelsus). Phase 2 produced ~14.7% weight loss at 36 weeks at the highest dose.
Primary uses
- Obesity — Phase 3
- Type 2 diabetes — Phase 3
Typical dosing
Phase 2 used 12, 24, 36 and 45 mg once daily. Phase 3 dosing tier TBD.
Regulatory status
Investigational. Developed by Eli Lilly (in-licensed from Chugai Pharmaceutical). In Phase 3 (ATTAIN obesity program, ACHIEVE diabetes program). Regulatory submissions anticipated 2026.
References
- [clinical-trial] Wharton S, et al. "Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (ATTAIN-1)." N Engl J Med, 2024.
- [clinical-trial] Frías JP, et al. "Efficacy and Safety of the Oral GLP-1 Receptor Agonist Orforglipron in Type 2 Diabetes." N Engl J Med, 2023;389:877-888.
- [clinical-trial] ClinicalTrials.gov NCT05869903 (ATTAIN-1, Phase 3 obesity).
Related peptides
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.